Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240012/S008

AeroPace System

Lungpacer Medical USA, Inc. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONP240012/S008

What did the FDA approve?

The FDA database lists decision APPR for supplement P240012/S008 to AeroPace® System, submitted by Lungpacer Medical USA, Inc., dated 2026-09-25. The supplement type is Real-Time Process with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The source statement describes approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console. The product code is SDL, categorized as a transvenous temporary phrenic nerve stimulator under Anesthesiology.

The P240012 prefix links this supplement to the original PMA of that number, but a supplement is not a new approval of the whole system. The statement reports a regulatory decision on specified component and packaging changes; it does not establish safety or clinical effectiveness. Specifics absent from the record include which temperature control components changed, the nature of the packaging changes, and any supporting data.

FDA approval order statement

Approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Anesthesiology
Decision date
Sep 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240012/S008
Regulatory pathway
PMA supplement
Product code
SDL
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transvenous temporary phrenic nerve stimulator.

Product code
SDL
FDA device class
3

For the original device and its historical approval scope, see PMA P240012. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240012/S008 received

    Application receipt date recorded by FDA.

  2. P240012/S008 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240012

Product / regulatory recordCompanyPathwayDecision dateSource
Lungpacer Medical USA, Inc.PMA approvalDec 4, 2024FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lungpacer Medical USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
260 Sierra Dr., Suite 116, Exton, PA, 19341

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records